

Cambodia Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms

1. Country:	Cam	bodia
-------------	-----	-------

2. Grant number: 19-KHM-12c-X /15-KHM-08c-Y

3. Date of Decision Letter: 5 March 2019

4. Date of the Partnership Framework Agreement (PFA): 6 November 2013

5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine

6. Vaccine type: Pneumococcal

7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID

8. Programme duration¹: 2015 -2019

9. Programme Budget (indicative): (subject to the terms of the PFA, if applicable)

	2015-2018	2019	Total ²
Programme Budget (US\$)	16,508,546 ³	4,731,000	21,239,546

10. Vaccine introduction grant (in US\$):

US\$ 275,500 paid on 16 June 2014

11. Indicative Annual Amounts: (subject to the terms of the PFA, if applicable)⁴

Type of supplies to be purchased with Gavi funds in each year	2015-2018	2019
Number of Pneumococcal vaccines doses		1,246,500
Annual Amounts (US\$)	16,508,546 ⁵	4,731,000

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. Self-procurement: Not applicable

Global Health Campus, Ch. du Pommier 40 1218 Grand-Saconnex, Geneva, Switzerland Tel. + 41 22 909 65 00 Fax + 41 22 909 65 50

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.



14. Co-financing obligations: Reference code: 19-KHM-12c-X-C According to the co-financing policy, the Country falls within the group Preparatory Transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019
Number of vaccine doses	127,000
Number of AD syringes	134,300
Number of re-constitution syringes	
Number of safety boxes	1,500
Value of vaccine doses (US\$)	418,782
Total co-financing payments (US\$) (including freight)	439,000

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: Not applicable

	Due dates
To prepare for the annual procurement of vaccines, Country shall	
submit the following information each year:	
 Vaccine stock levels including buffer stock, by end March; Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or 	31 March 2019
minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.	15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,

On behalf of Gavi

Hind Khatib-Othman

disal . To bail

Managing Director, Country Programmes

5 March 2019